Entrada Therapeutics Inc. (TRDA)
Company Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1.
The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dipal Doshi |
Contact Details
Address: 6 Tide Street Boston, Massachusetts United States | |
| Website | https://www.entradatx.com |
Stock Details
| Ticker Symbol | TRDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001689375 |
| CUSIP Number | 29384C108 |
| ISIN Number | US29384C1080 |
| Employer ID | 81-3983399 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dipal Doshi | Chief Executive Officer & Director |
| Kory James Wentworth CPA | Chief Financial Officer & Treasurer |
| Nathan J. Dowden | President & Chief Operating Officer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
| Dr. Natarajan Sethuraman Ph.D. | President of Research & Development |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kerry Robert M.S. | Senior Vice President of People |
| Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs |
| Leo Qian Ph.D. | Co-Founder & Vice President of Discovery Research |
| Murali Mallem | Vice President & Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | S-8 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 04, 2025 | SCHEDULE 13G | Filing |
| Feb 03, 2025 | 8-K | Current Report |
| Jan 15, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 4 | Filing |